Skip to content

KDIGO 2026: anaemia in CKD

International KDIGO Current

KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes Anemia Work Group. Kidney Int. 2026;109(1S):S1–S99
Summary checked against the source: 2026-11

Read or download the original

This guideline replaces the KDIGO 2012 anaemia guideline. Almost all of it is practice points (PP); the few graded recommendations are mostly 2D. It adds guidance on HIF-PHIs (roxadustat, daprodustat, vadadustat).

At a glance

  1. Test for anaemia at referral and regularly: yearly in G3, twice a year in G4, every 3 months in G5/G5D. Use FBC, reticulocytes, ferritin and TSAT. [PP · S16–S17]
  2. Iron first. Haemodialysis: start IV iron if ferritin ≤500 and TSAT ≤30%. [2D · S20]
  3. Not on haemodialysis: iron if ferritin <100 with TSAT <40%, or ferritin 100–300 with TSAT <25%; oral or IV. [2D · S20]
  4. ESA rather than HIF-PHI as first line, after correcting other causes. [2D · S23]
  5. Start ESA on dialysis at Hb ≤9–10 g/dL. Target Hb below 11.5 g/dL. [2D · S24; 1D · S24]
  6. Transfuse for symptoms, not a number, and avoid it in transplant candidates. [PP · S28]

Evaluation

CKD stage Check Hb at least
G3 Yearly
G4 Twice a year
G5, G5D Every 3 months

Adapted from KDIGO 2026 Figure 5 [S17]

  • First tests: FBC, reticulocytes (reticulocyte production index), ferritin, TSAT. [PP 1.2.1 · S17]
  • If unexplained: smear, haptoglobin, LDH, CRP, B12, folate, LFTs, myeloma screen (SPEP, free light chains, Bence-Jones), TSH, PTH, faecal occult blood. [PP 1.2.2 · S17]
  • Ferritin <45 ng/mL or MCV <80 fL without a clear cause: look for blood loss (GI, gynaecological, urological). [PP 1.2.3 · S17]

Iron

Population Start iron if Route
Haemodialysis Ferritin ≤500 ng/mL and TSAT ≤30% IV, proactive dosing to keep stores stable
Not on dialysis, or peritoneal dialysis Ferritin <100 and TSAT <40%, or ferritin 100–300 and TSAT <25% Oral or IV by preference, severity, tolerability, cost
CKD with profound iron deficiency but no anaemia (ferritin <30, TSAT <20%) Consider iron Oral or IV

Adapted from KDIGO 2026 recommendations 2.1–2.4 and PP 2.11 [S20–S22]

  • Hold routine iron if ferritin >700 ng/mL or TSAT ≥40%. [PP 2.2 · S20]
  • Check Hb, ferritin and TSAT every 3 months (every 1–3 months on haemodialysis). [PP 2.5 · S20]
  • Switch oral to IV if oral iron isn't enough after 1–3 months or isn't tolerated. Pause iron during systemic infection. [PP 2.7–2.8 · S21]

ESA and HIF-PHI

Graded recommendations [S23–S24]

  • Correct other causes first, then an ESA rather than a HIF-PHI. [2D · S23]
  • Dialysis: start an ESA when Hb is ≤9.0–10.0 g/dL. [2D · S24]
  • Not on dialysis (including transplant recipients and children): choose the starting Hb by symptoms and the balance of benefit and harm. [2D · S24]

Target: Hb below 11.5 g/dL [1D · S24]

In adults on an ESA, target Hb below 11.5 g/dL (115 g/L). Higher targets raise the risk of stroke, hypertension and access thrombosis.

Point Practice
Dose changes Not more often than every 4 weeks; cut by 25–50% if Hb rises >1 g/dL in 2–4 weeks
Route Subcutaneous if not on dialysis, on PD or transplanted; IV or SC on haemodialysis
Monitoring Hb every 2–4 weeks after starting or changing dose; at least every 3 months in maintenance
Suspend During admission for acute stroke, access thrombosis or thromboembolism
Cancer Shared decision, especially when treatment aims at cure
Never ESA and HIF-PHI together
HIF-PHI Same Hb thresholds as ESA; labelled starting doses, never above the maximum; Hb at 2–4 weeks then monthly; stop if no response in 3–4 months; check thyroid function with roxadustat
Avoid HIF-PHI Active cancer, recent cardiovascular event, recent vascular thrombosis
ESA hyporesponsiveness Find and treat causes (iron deficiency, inflammation, hyperparathyroidism, inadequate dialysis, haemolysis, marrow disorders); a HIF-PHI trial can be considered

Adapted from KDIGO 2026 sections 3.4–3.7 [S25–S27]

Transfusion

  • Part of an overall strategy, decided with the patient. Base the decision on symptoms, not an arbitrary Hb. [PP 4.1, 4.4 · S28]
  • Avoid in transplant candidates to prevent allosensitisation. [PP 4.2 · S28]
  • Benefits may outweigh harms when ESA or HIF-PHI is ineffective (haemoglobinopathy, marrow failure, resistance) or harmful (e.g. cancer, previous stroke), and in acute bleeding, unstable coronary disease or before urgent surgery. [PP 4.3, 4.5 · S28]

Clinical pearls

  • Iron before ESA; check ferritin and TSAT.
  • Haemodialysis threshold: ferritin ≤500, TSAT ≤30% → IV iron.
  • ESA target Hb <11.5 g/dL; don't aim for normal (TREAT, CHOIR).
  • Commonest cause of ESA hyporesponsiveness: iron deficiency.
  • HIF-PHIs (roxadustat) are oral, but avoid them with cancer or recent thrombosis.

Classes and levels of evidence

How KDIGO Anaemia 2026 grades its recommendations. Adapted from KDIGO Anaemia 2026 grading system [S1–S99]. Hover over any class or level cited on this page to see what it means.

Grade Meaning Wording used
1A Level 1, strong: we recommend. Most people would want this course of action; quality A (high): we are confident that the true effect is close to the estimate
1B Level 1, strong: we recommend. Most people would want this course of action; quality B (moderate): the true effect is likely close to the estimate but may be substantially different
1C Level 1, strong: we recommend. Most people would want this course of action; quality C (low): the true effect may be substantially different
1D Level 1, strong: we recommend. Most people would want this course of action; quality D (very low): the estimate is very uncertain and often far from the truth
2A Level 2, weak: we suggest. Most people would want it, but many would not; quality A (high): we are confident that the true effect is close to the estimate
2B Level 2, weak: we suggest. Most people would want it, but many would not; quality B (moderate): the true effect is likely close to the estimate but may be substantially different
2C Level 2, weak: we suggest. Most people would want it, but many would not; quality C (low): the true effect may be substantially different
2D Level 2, weak: we suggest. Most people would want it, but many would not; quality D (very low): the estimate is very uncertain and often far from the truth
Practice point Ungraded expert advice where a systematic review was not done
Not graded Ungraded statement based on common sense, or on a topic with no basis for grading evidence

KDIGO grades each recommendation by strength (1 = "we recommend", 2 = "we suggest") and quality of evidence (A high, B moderate, C low, D very low), written together as 1B, 2C and so on. Practice points (PP) are ungraded expert advice where no systematic review was done. Older KDIGO guidelines also have "Not Graded" statements.